Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment

Westermann, 1997, Growth factors in human ovarian cancer, Cancer Treat. Rev., 23, 113, 10.1016/S0305-7372(97)90024-4

Amsterdam, 2010, Novel role of growth factors in ovary function, Harefuah, 149, 789

Thibault, 2014, Ovarian cancer microenvironment: Implications for cancer dissemination and chemoresistance acquisition, Cancer Metastasis Rev., 33, 17, 10.1007/s10555-013-9456-2

Luo, 2016, Tumor microenvironment: The culprit for ovarian cancer metastasis?, Cancer Lett., 377, 174, 10.1016/j.canlet.2016.04.038

Hodeib, 2015, A review of HER2-targeted therapy in breast and ovarian cancer: Lessons from antiquity—Cleopatra and Penelope, Future Oncol., 11, 3113, 10.2217/fon.15.266

Fotopoulos, 2016, The emerging role of tyrosine kinase inhibitors in ovarian cancer treatment: A systematic review, Cancer Investig., 34, 313, 10.1080/07357907.2016.1206117

Cai, H., Chiorean, E.G., Chiorean, M.V., Rex, D.K., Robb, B.W., Hahn, N.M., Liu, Z., Loehrer, P.J., Harrison, M.L., and Xu, Y. (2013). Elevated phospholipase A2 activities in plasma samples from multiple cancers. PLoS ONE, 8.

Pap, 2009, Highlights of a new type of intercellular communication: Microvesicle-based information transfer, Inflamm. Res., 58, 1, 10.1007/s00011-008-8210-7

He, 2018, Exosome theranostics: Biology and translational medicine, Theranostics, 8, 237, 10.7150/thno.21945

Taylor, 2008, MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer, Gynecol. Oncol., 110, 13, 10.1016/j.ygyno.2008.04.033

Beach, 2014, Exosomes: An overview of biogenesis, composition and role in ovarian cancer, J. Ovarian Res., 7, 14, 10.1186/1757-2215-7-14

Saleem, 2015, Tumor-derived exosomes in oncogenic reprogramming and cancer progression, Cell. Mol. Life Sci., 72, 1, 10.1007/s00018-014-1710-4

Cheng, 2017, A comprehensive overview of exosomes in ovarian cancer: Emerging biomarkers and therapeutic strategies, J. Ovarian Res., 10, 73, 10.1186/s13048-017-0368-6

Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Amoroso, 2017, Stress-adaptive response in ovarian cancer drug resistance: Role of trap1 in oxidative metabolism-driven inflammation, Adv. Protein Chem. Struct. Biol., 108, 163, 10.1016/bs.apcsb.2017.01.004

Ke, 2016, Metabolic phenotyping for monitoring ovarian cancer patients, Sci. Rep., 6, 23334, 10.1038/srep23334

Fahy, 2009, Update of the lipid maps comprehensive classification system for lipids, J. Lipid Res., 50, S9, 10.1194/jlr.R800095-JLR200

Tania, 2010, Association of lipid metabolism with ovarian cancer, Curr. Oncol., 17, 6, 10.3747/co.v17i5.668

Tsujiuchi, 2014, Lysophosphatidic acid receptors in cancer pathobiology, Histol. Histopathol., 29, 313

Pua, 2009, Roles of LPA in ovarian cancer development and progression, Future Oncol., 5, 1659, 10.2217/fon.09.120

Tokumura, 2002, Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase d in body fluids, Biochim. Biophys. Acta, 1582, 18, 10.1016/S1388-1981(02)00133-6

Turkoglu, O., Zeb, A., Graham, S., Szyperski, T., Szender, J.B., Odunsi, K., and Bahado-Singh, R. (2016). Metabolomics of biomarker discovery in ovarian cancer: A systematic review of the current literature. Metabolomics, 12.

Rice, 2017, The crosstalk between ovarian cancer stem cell niche and the tumor microenvironment, Stem Cells Int., 2017, 5263974

Ray, 2017, Gene regulatory networking reveals the molecular cue to lysophosphatidic acid-induced metabolic adaptations in ovarian cancer cells, Mol. Oncol., 11, 491, 10.1002/1878-0261.12046

Xu, 1995, Lysophospholipids activate ovarian and breast cancer cells, Biochem. J., 309, 933, 10.1042/bj3090933

Xu, 1995, Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients, Clin. Cancer Res., 1, 1223

Benesch, M.G.K., MacIntyre, I.T.K., McMullen, T.P.W., and Brindley, D.N. (2018). Coming of age for autotaxin and lysophosphatidate signaling: Clinical applications for preventing, detecting and targeting tumor-promoting inflammation. Cancers, 10.

Xiao, 2001, Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: Comparison of the lysophospholipid contents in malignant vs. nonmalignant ascitic fluids, Anal. Biochem., 290, 302, 10.1006/abio.2001.5000

Xu, 1995, Effect of lysophospholipids on signaling in the human jurkat T cell line, J. Cell. Physiol., 163, 441, 10.1002/jcp.1041630303

Sengupta, 2004, Biology of lpa in health and disease, Semin. Cell Dev. Biol., 15, 503, 10.1016/j.semcdb.2004.05.003

Mills, 2003, The emerging role of lysophosphatidic acid in cancer, Nat. Rev. Cancer, 3, 582, 10.1038/nrc1143

Murph, 2007, Targeting the lipids LPA and S1p and their signalling pathways to inhibit tumour progression, Expert. Rev. Mol. Med., 9, 1, 10.1017/S1462399407000476

Xu, 1998, Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers, JAMA, 280, 719, 10.1001/jama.280.8.719

Sutphen, 2004, Lysophospholipids are potential biomarkers of ovarian cancer, Cancer Epidemiol. Biomarkers Prev., 13, 1185, 10.1158/1055-9965.1185.13.7

Xiao, 2000, Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses, Ann. N. Y. Acad. Sci., 905, 242, 10.1111/j.1749-6632.2000.tb06554.x

Sedlakova, 2006, Lysophosphatidic acid in ovarian cancer patients, Ceska Gynekol., 71, 312

Meleh, 2007, Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 858, 287, 10.1016/j.jchromb.2007.08.008

Sedlakova, 2008, Lysophosphatidic acid: An ovarian cancer marker, Eur. J. Gynaecol. Oncol., 29, 511

Nakamura, 2012, Serum autotaxin is not a useful biomarker for ovarian cancer, Lipids, 47, 927, 10.1007/s11745-012-3691-0

Lu, 2015, Diagnostic value of total plasma lysophosphatidic acid in ovarian cancer: A meta-analysis, Int. J. Gynecol. Cancer, 25, 18, 10.1097/IGC.0000000000000319

Zhang, 2015, Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer, J. Cancer Res. Ther., 11, 375, 10.4103/0973-1482.157335

Li, 2015, Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: A meta-analysis, Lipids Health Dis., 14, 72, 10.1186/s12944-015-0071-9

Westermann, 1998, Malignant effusions contain lysophosphatidic acid (LPA)-like activity, Ann. Oncol., 9, 437, 10.1023/A:1008217129273

Cai, 2012, Elevated and secreted phospholipase A(2) activities as new potential therapeutic targets in human epithelial ovarian cancer, FASEB J., 26, 3306, 10.1096/fj.12-207597

Murph, 2007, Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: Potential biomarkers for cancer diagnosis, Methods Enzymol., 433, 1, 10.1016/S0076-6879(07)33001-2

Zhao, 2010, An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples, J. Lipid Res., 51, 652, 10.1194/jlr.D001503

Michels, 2015, Decreased plasma levels of the endothelial protective sphingosine-1-phosphate are associated with dengue-induced plasma leakage, J. Infect., 71, 480, 10.1016/j.jinf.2015.06.014

Ramanathan, 2017, Paradoxical association of postoperative plasma sphingosine-1-phosphate with breast cancer aggressiveness and chemotherapy, Mediators Inflamm., 2017, 5984819, 10.1155/2017/5984819

Ma, 2010, Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain, J. Pharmacol. Exp. Ther., 333, 540, 10.1124/jpet.109.164830

Eder, 2000, Constitutive and lysophosphatidic acid (LPA)-induced LPA production: Role of phospholipase D and phospholipase a2, Clin. Cancer Res., 6, 2482

Sengupta, 2003, A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells, FASEB J., 17, 1570, 10.1096/fj.02-1145fje

Shen, 1998, Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells, Gynecol. Oncol., 71, 364, 10.1006/gyno.1998.5193

Aoki, 2004, Mechanisms of lysophosphatidic acid production, Semin. Cell. Dev. Biol., 15, 477, 10.1016/j.semcdb.2004.05.001

Benesch, 2016, Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo, J. Biomed. Res., 30, 272, 10.7555/JBR.30.20150058

Nikolaou, 2017, Autotaxin inhibitors: A patent review (2012–2016), Expert. Opin. Ther. Pat., 27, 815, 10.1080/13543776.2017.1323331

Gaits, 1997, Lysophosphatidic acid as a phospholipid mediator: Pathways of synthesis, FEBS Lett., 410, 54, 10.1016/S0014-5793(97)00411-0

Pages, 2001, Lysophosphatidic acid synthesis and release, Prostaglandins Other Lipid Mediat., 64, 1, 10.1016/S0090-6980(01)00110-1

Roszkowski, 1971, Problems of surgical treatment of a patient with blood platelet disorders, Ginekol. Pol., 42, 1499

Hisada, 2015, Venous thrombosis and cancer: From mouse models to clinical trials, J. Thromb. Haemost., 13, 1372, 10.1111/jth.13009

Menczer, 2017, Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies, Arch. Gynecol. Obstet., 295, 9, 10.1007/s00404-016-4212-9

Swier, 2017, Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression, Thromb. Res., 150, 8, 10.1016/j.thromres.2016.12.002

Zhou, 2018, Clinicopathological and prognostic significance of platelet count in patients with ovarian cancer, Climacteric, 21, 60, 10.1080/13697137.2017.1406911

Lin, 2014, Paraneoplastic thrombocytosis: The secrets of tumor self-promotion, Blood, 124, 184, 10.1182/blood-2014-03-562538

Nugent, 1999, The synergistic interactions of oleoyl-lysophosphatidic acid in platelet aggregation, Med. Sci. Res., 27, 435

Nugent, 2000, Sphingosine-1-phosphate: Characterization of its inhibition of platelet aggregation, Platelets, 11, 226, 10.1080/09537100050057675

Leblanc, R., Houssin, A., and Peyruchaud, O. (2018). Platelets, autotaxin and lysophosphatidic acid signaling: Win-win factors for cancer metastasis. Br. J. Pharmacol.

Krishnan, V., Clark, R., Chekmareva, M., Johnson, A., George, S., Shaw, P., Seewaldt, V., and Rinker-Schaeffer, C. (2015). In vivo and ex vivo approaches to study ovarian cancer metastatic colonization of milky spot structures in peritoneal adipose. J. Vis. Exp., e52721.

Feist, 2018, Quantitative proteomic analysis of murine white adipose tissue for peritoneal cancer metastasis, Anal. Bioanal. Chem., 410, 1583, 10.1007/s00216-017-0813-9

Cai, 2015, Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells, Oncogene, 34, 3315, 10.1038/onc.2014.264

Nieman, 2011, Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth, Nat. Med., 17, 1498, 10.1038/nm.2492

Kishi, 2002, Autotaxin has lysophospholipase d activity leading to tumor cell growth and motility by lysophosphatidic acid production, J. Cell. Biol., 158, 227, 10.1083/jcb.200204026

Benesch, 2015, Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate, J. Lipid Res., 56, 1134, 10.1194/jlr.M057661

Volden, 2016, Mammary adipose tissue-derived lysophospholipids promote estrogen receptor-negative mammary epithelial cell proliferation, Cancer Prev. Res., 9, 367, 10.1158/1940-6207.CAPR-15-0107

Dusaulcy, 2011, Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid, J. Lipid Res., 52, 1247, 10.1194/jlr.M014985

Benesch, 2017, Lysophosphatidate signaling: The tumor microenvironment’s new nemesis, Trends Cancer, 3, 748, 10.1016/j.trecan.2017.09.004

Ren, 2006, Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells, Cancer Res., 66, 3006, 10.1158/0008-5472.CAN-05-1292

Knowlden, 2014, The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation, J. Immunol., 192, 851, 10.4049/jimmunol.1302831

Halama, 2017, Nesting of colon and ovarian cancer cells in the endothelial niche is associated with alterations in glycan and lipid metabolism, Sci. Rep., 7, 39999, 10.1038/srep39999

Wong, 2016, Synergistic COX2 induction by IFNgamma and TNFalpha self-limits type-1 immunity in the human tumor microenvironment, Cancer Immunol. Res., 4, 303, 10.1158/2326-6066.CIR-15-0157

Reinartz, 2016, A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome, Genome Biol., 17, 108, 10.1186/s13059-016-0956-6

Nakayama, J., Raines, T.A., Lynch, K.R., and Slack-Davis, J.K. (2015). Decreased peritoneal ovarian cancer growth in mice lacking expression of lipid phosphate phosphohydrolase 1. PLoS ONE, 10.

Baudhuin, 2002, AKT activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific, Mol. Pharmacol., 62, 660, 10.1124/mol.62.3.660

Cai, 2013, The role of lpa and yap signaling in long-term migration of human ovarian cancer cells, Cell Commun. Signal., 11, 31, 10.1186/1478-811X-11-31

Fan, 2017, The novel zip4 regulation and its role in ovarian cancer, Oncotarget, 8, 90090, 10.18632/oncotarget.21435

Fan, Q., Cai, Q., and Xu, Y. (2017). LPA Regulates sox9 in Ovarian Cancer Cells, Gavin Publishers.

Fang, 2004, Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells, J. Biol. Chem., 279, 9653, 10.1074/jbc.M306662200

Ha, 2016, Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker slug/snail2 in ovarian cancer cells via galphai2, src, and hif1alpha signaling nexus, Oncotarget, 7, 37664, 10.18632/oncotarget.9224

Jiang, 2005, Kiss1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase c alpha, Clin. Exp. Metastasis, 22, 369, 10.1007/s10585-005-8186-4

Kim, 2006, Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo, Cancer Res., 66, 7983, 10.1158/0008-5472.CAN-05-4381

Li, 2009, Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice, Mol. Cancer Ther., 8, 1692, 10.1158/1535-7163.MCT-08-1106

Li, 2010, Group via phospholipase a2 in both host and tumor cells is involved in ovarian cancer development, FASEB J., 24, 4103, 10.1096/fj.10-161356

Lu, 2002, Role of ether-linked lysophosphatidic acids in ovarian cancer cells, J. Lipid Res., 43, 463, 10.1016/S0022-2275(20)30153-X

Ren, 2010, Effect of inhibitors of phospholipase A(2); on the metastasis potentials of human ovarian cancer cells, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 26, 992

Schwartz, 2001, Lysophospholipids increase interleukin-8 expression in ovarian cancer cells, Gynecol. Oncol., 81, 291, 10.1006/gyno.2001.6124

Sengupta, 2007, Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion, Oncogene, 26, 2894, 10.1038/sj.onc.1210093

Fang, 2000, Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer, Ann. N. Y. Acad. Sci., 905, 188, 10.1111/j.1749-6632.2000.tb06550.x

Fang, 2002, Lysophosphatidic acid is a bioactive mediator in ovarian cancer, Biochim. Biophys. Acta, 1582, 257, 10.1016/S1388-1981(02)00179-8

Mills, 2002, Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer, Cancer Treat. Res., 107, 259

Yung, 2014, Lpa receptor signaling: Pharmacology, physiology, and pathophysiology, J. Lipid Res., 55, 1192, 10.1194/jlr.R046458

Jesionowska, 2015, Lysophosphatidic acid signaling in ovarian cancer, J. Recept Signal. Transduct. Res., 35, 578, 10.3109/10799893.2015.1026444

Wang, 2008, Inhibition of lysophosphatidic acid receptor-2 expression by rna interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells, Croat Med. J., 49, 175, 10.3325/cmj.2008.2.175

Yang, 2008, Lysophosphatidic acid activates telomerase in ovarian cancer cells through hypoxia-inducible factor-1alpha and the PI3K pathway, J. Cell Biochem., 105, 1194, 10.1002/jcb.21919

Bai, 2014, Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions, J. Thorac. Dis., 6, 483

Fan, 2015, Foxm1 is a downstream target of lpa and yap oncogenic signaling pathways in high grade serous ovarian cancer, Oncotarget, 6, 27688, 10.18632/oncotarget.4280

Fishman, 2001, Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and mmp-dependent invasion in ovarian cancer cells, Cancer Res., 61, 3194

Burkhalter, 2015, Lysophosphatidic acid initiates epithelial to mesenchymal transition and induces beta-catenin-mediated transcription in epithelial ovarian carcinoma, J. Biol. Chem., 290, 22143, 10.1074/jbc.M115.641092

Cui, 2017, The roles of glycodelin in cancer development and progression, Front. Immunol., 8, 1685, 10.3389/fimmu.2017.01685

Xu, 2003, Unfolding the pathophysiological role of bioactive lysophospholipids, Curr. Drug Targets Immune Endocr. Metabol. Disord., 3, 23, 10.2174/1568005310303010023

Li, H., and Xu, Y. (2007). Unpublished observation.

Seo, 2016, Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism, Stem Cells, 34, 551, 10.1002/stem.2279

Bar-Shavit, R., Maoz, M., Kancharla, A., Nag, J.K., Agranovich, D., Grisaru-Granovsky, S., and Uziely, B. (2016). G protein-coupled receptors in cancer. Int. J. Mol. Sci., 17.

Taniguchi, 2017, Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA6, Nature, 548, 356, 10.1038/nature23448

Hope, 2009, LPA receptor 2 mediates LPA-induced endometrial cancer invasion, Gynecol. Oncol., 112, 215, 10.1016/j.ygyno.2008.09.019

Lin, 2009, The absence of lpa2 attenuates tumor formation in an experimental model of colitis-associated cancer, Gastroenterology, 136, 1711, 10.1053/j.gastro.2009.01.002

Stoddard, 2015, Promising pharmacological directions in the world of lysophosphatidic acid signaling, Biomol. Ther., 23, 1, 10.4062/biomolther.2014.109

Takahashi, 2017, Lysophosphatidic acid (LPA) signaling via LPA4 and LPA6 negatively regulates cell motile activities of colon cancer cells, Biochem. Biophys. Res. Commun., 483, 652, 10.1016/j.bbrc.2016.12.088

Ishii, 2015, Diverse effects of LPA4, LPA5 and LPA6 on the activation of tumor progression in pancreatic cancer cells, Biochem. Biophys. Res. Commun., 461, 59, 10.1016/j.bbrc.2015.03.169

Takahashi, 2018, Effects of LPA1 and LPA6 on the regulation of colony formation activity in colon cancer cells treated with anticancer drugs, J. Recept. Signal. Transduct. Res., 38, 71, 10.1080/10799893.2018.1426608

McIntyre, 2003, Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular ppargamma agonist, Proc. Natl. Acad. Sci. USA, 100, 131, 10.1073/pnas.0135855100

Tsukahara, 2006, Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma, J. Biol. Chem., 281, 3398, 10.1074/jbc.M510843200

Tsukahara, 2013, Ppar gamma networks in cell signaling: Update and impact of cyclic phosphatidic acid, J. Lipids, 2013, 246597, 10.1155/2013/246597

Tsukahara, 2013, Effect of alkyl glycerophosphate on the activation of peroxisome proliferator-activated receptor gamma and glucose uptake in C2C12 cells, Biochem. Biophys. Res. Commun., 433, 281, 10.1016/j.bbrc.2013.02.101

Worzfeld, 2018, Proteotranscriptomics reveal signaling networks in the ovarian cancer microenvironment, Mol. Cell. Proteom., 17, 270, 10.1074/mcp.RA117.000400

Knowlden, S.A., Capece, T., Popovic, M., Chapman, T.J., Rezaee, F., Kim, M., and Georas, S.N. (2014). Regulation of T cell motility in vitro and in vivo by LPA and LPA2. PLoS ONE, 9.

Okita, 1997, Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysopc) in ovarian cancer patients, Int. J. Cancer, 71, 31, 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4

Zhang, 2016, High resolution mass spectrometry coupled with multivariate data analysis revealing plasma lipidomic alteration in ovarian cancer in asian women, Talanta, 150, 88, 10.1016/j.talanta.2015.12.021

Zhao, 2007, Plasma lysophosphatidylcholine levels: Potential biomarkers for colorectal cancer, J. Clin. Oncol., 25, 2696, 10.1200/JCO.2006.08.5571

Zhao, 2009, Measurement of endogenous lysophosphatidic acid by ESI-MS/MS in plasma samples requires pre-separation of lysophosphatidylcholine, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 877, 3739, 10.1016/j.jchromb.2009.08.032

Ross, 2016, The molecular mechanism by which saturated lysophosphatidylcholine attenuates the metastatic capacity of melanoma cells, FEBS Open Bio, 6, 1297, 10.1002/2211-5463.12152

Kuhn, T., Floegel, A., Sookthai, D., Johnson, T., Rolle-Kampczyk, U., Otto, W., von Bergen, M., Boeing, H., and Kaaks, R. (2016). Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study. BMC Med., 14.

Goto, 2015, Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer, Prostate, 75, 1821, 10.1002/pros.23088

Song, 2007, Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells, Biochem. J., 406, 427, 10.1042/BJ20070631

Li, 2011, Combination therapy of an inhibitor of group via phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development, Am. J. Pathol., 179, 452, 10.1016/j.ajpath.2011.03.027

Carneiro, A.B., Iaciura, B.M., Nohara, L.L., Lopes, C.D., Veas, E.M., Mariano, V.S., Bozza, P.T., Lopes, U.G., Atella, G.C., and Almeida, I.C. (2013). Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced no synthesis in peritoneal macrophages by inhibiting NF-kappab translocation and MAPK/ERK phosphorylation. PLoS ONE, 8.

Li, 2016, Mitochondrial reactive oxygen species mediate lysophosphatidylcholine-induced endothelial cell activation, Arterioscler. Thromb. Vasc. Biol., 36, 1090, 10.1161/ATVBAHA.115.306964

Dufourcq, 1979, Lipid-protein interactions: NMR study of melittin and its binding to lysophosphatidylcholine, Biochim. Biophys. Acta, 552, 531, 10.1016/0005-2736(79)90197-4

Kim, 2007, Albumin inhibits cytotoxic activity of lysophosphatidylcholine by direct binding, Prostaglandins Other Lipid Mediat., 83, 130, 10.1016/j.prostaglandins.2006.10.006

Mina, 2018, Oncogenic signaling pathways in the cancer genome atlas, Cell, 173, 321, 10.1016/j.cell.2018.03.035

Li, X., Wang, L., Fang, P., Sun, Y., Jiang, X., Wang, H., and Yang, X.F. (2018). Lysophospholipids induce innate immune transdifferentiation of endothelial cells, resulting in prolonged endothelial activation. J. Biol. Chem.

Hurst, 2017, A putative lysophosphatidylinositol receptor GPR55 modulates hippocampal synaptic plasticity, Hippocampus, 27, 985, 10.1002/hipo.22747

Zhao, 2016, The lipidomic analyses in low and highly aggressive ovarian cancer cell lines, Lipids, 51, 179, 10.1007/s11745-015-4108-7

Cannavo, 2017, Sphingosine kinases and sphingosine 1-phosphate receptors: Signaling and actions in the cardiovascular system, Front. Pharmacol., 8, 556, 10.3389/fphar.2017.00556

Hatoum, 2017, Mammalian sphingosine kinase (SPHK) isoenzymes and isoform expression: Challenges for sphk as an oncotarget, Oncotarget, 8, 36898, 10.18632/oncotarget.16370

Rodriguez, 2016, Sphingosine-1 phosphate: A new modulator of immune plasticity in the tumor microenvironment, Front. Oncol., 6, 218, 10.3389/fonc.2016.00218

Nagahashi, 2014, Sphingosine-1-phosphate transporters as targets for cancer therapy, Biomed. Res. Int., 2014, 651727, 10.1155/2014/651727

Kunkel, 2013, Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond, Nat. Rev. Drug Discov., 12, 688, 10.1038/nrd4099

Kostenis, 2004, Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: New receptors for “old” ligands, J. Cell. Biochem., 92, 923, 10.1002/jcb.20092

Kang, 2004, Serum bioactive lysophospholipids prevent trail-induced apoptosis via PI3K/AKT-dependent cflip expression and bad phosphorylation, Cell Death Differ., 11, 1287, 10.1038/sj.cdd.4401489

Park, 2007, S1p stimulates chemotactic migration and invasion in ovcar3 ovarian cancer cells, Biochem. Biophys Res. Commun., 356, 239, 10.1016/j.bbrc.2007.02.112

Dai, 2014, Sphingosine 1-phosphate: A potential molecular target for ovarian cancer therapy?, Cancer Investig., 32, 71, 10.3109/07357907.2013.876646

Jin, 2016, The SPHKS/S1P/S1PR1 axis in immunity and cancer: More ore to be mined, World J. Surg. Oncol., 14, 131, 10.1186/s12957-016-0884-7

Hong, 1999, Sphingosine-1-phosphate modulates growth and adhesion of ovarian cancer cells, FEBS Lett., 460, 513, 10.1016/S0014-5793(99)01400-3

Baudhuin, 2004, S1p3-mediated AKT activation and cross-talk with platelet-derived growth factor receptor (PDGFR), FASEB J., 18, 341, 10.1096/fj.03-0302fje

Wang, 2008, S1p differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells, Mol. Cancer Ther., 7, 1993, 10.1158/1535-7163.MCT-08-0088

Devine, 2008, S1p induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by GI and RAC, Gynecol. Oncol., 110, 237, 10.1016/j.ygyno.2008.04.013

Smicun, 2007, S1p and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells, Gynecol. Oncol., 107, 298, 10.1016/j.ygyno.2007.06.024

Smicun, 2006, S1p regulation of ovarian carcinoma invasiveness, Gynecol. Oncol., 103, 952, 10.1016/j.ygyno.2006.06.036

Zachmann, 2017, Ligand chain length drives activation of lipid g protein-coupled receptors, Sci. Rep., 7, 2020, 10.1038/s41598-017-02104-5

Dai, 2017, Sphingosine kinase 1/sphingosine-1-phosphate (S1p)/S1p receptor axis is involved in ovarian cancer angiogenesis, Oncotarget, 8, 74947, 10.18632/oncotarget.20471

Fyrst, 2010, An update on sphingosine-1-phosphate and other sphingolipid mediators, Nat. Chem. Biol., 6, 489, 10.1038/nchembio.392

Illuzzi, 2010, Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells, J. Biol. Chem., 285, 18594, 10.1074/jbc.M109.072801

Snider, 2010, Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation, Biochimie, 92, 707, 10.1016/j.biochi.2010.02.008

Hait, 2009, Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate, Science, 325, 1254, 10.1126/science.1176709

Patmanathan, 2017, Mechanisms of sphingosine 1-phosphate receptor signalling in cancer, Cell Signal., 34, 66, 10.1016/j.cellsig.2017.03.002

Fan, 2017, Sphingosine-1-phosphate promotes ovarian cancer cell proliferation by disrupting hippo signaling, Oncotarget, 8, 27166, 10.18632/oncotarget.15677

Wen, 2015, MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1, Mol. Med. Rep., 12, 3775, 10.3892/mmr.2015.3827

Du, 2010, S1p(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice, Cancer Res., 70, 772, 10.1158/0008-5472.CAN-09-2722

Dai, 2018, Effect of S1PR2 inhibition on epithelial ovarian cancer SKOV3 cell proliferation in vitro and in vivo, Zhonghua Fu Chan Ke Za Zhi, 53, 106

Michaud, 2010, Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation, J. Immunol., 184, 1475, 10.4049/jimmunol.0901586

Goetzl, 1999, Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer, Cancer Res., 59, 5370

Argraves, 2010, Sphingosine-1-phosphate signaling in vasculogenesis and angiogenesis, World J. Biol. Chem., 1, 291, 10.4331/wjbc.v1.i10.291

Lucke, 2010, Endothelial functions of sphingosine-1-phosphate, Cell. Physiol. Biochem., 26, 87, 10.1159/000315109

Kim, 2005, GPR4 plays a critical role in endothelial cell function and mediates the effects of sphingosylphosphorylcholine, FASEB J., 19, 819, 10.1096/fj.04-2988fje

Beach, 2016, Sphingosine kinase 1 is required for TGF-beta mediated fibroblastto- myofibroblast differentiation in ovarian cancer, Oncotarget, 7, 4167, 10.18632/oncotarget.6703

Shida, 2008, Targeting SPHK1 as a new strategy against cancer, Curr. Drug Targets, 9, 662, 10.2174/138945008785132402

Visentin, 2006, Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages, Cancer Cell, 9, 225, 10.1016/j.ccr.2006.02.023

Siegel, 2018, Cancer statistics, 2018, CA Cancer J. Clin., 68, 7, 10.3322/caac.21442

Domcke, 2013, Evaluating cell lines as tumour models by comparison of genomic profiles, Nat. Commun., 4, 2126, 10.1038/ncomms3126

Beaufort, C.M., Helmijr, J.C., Piskorz, A.M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van, I.W.F., Heine, A.A., and Smid, M. (2014). Ovarian cancer cell line panel (OCCP): Clinical importance of in vitro morphological subtypes. PLoS ONE, 9.

Lee, 2006, Sphingosylphosphorylcholine stimulates human monocyte-derived dendritic cell chemotaxis, Acta Pharmacol. Sin., 27, 1359, 10.1111/j.1745-7254.2006.00426.x

Ceballos, 2007, Sphingosylphosphorylcholine activates dendritic cells, stimulating the production of interleukin-12, Immunology, 121, 328, 10.1111/j.1365-2567.2007.02578.x